Barry Ticho

Linde (United States) — United States

Medicine · Health Sciences

17h-index2.2kcitations38works9.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Heart Failure Treatment and Management(8), Adenosine and Purinergic Signaling(7), Polyomavirus and related diseases(5), Acute Kidney Injury Research(4), Antibiotics Pharmacokinetics and Efficacy(4)

Publications38 total

Natural History of Children and Adolescents With Dravet Syndrome
Neurology·2025· 2 citedOpen Access
Adaptive functioning and neurodevelopment in patients with Dravet syndrome: 12-month interim analysis of the BUTTERFLY observational study
Epilepsy & Behavior·2024· 17 citedOpen Access
Interim results of adaptive functioning and neurodevelopment in BUTTERFLY – An observational study of children and adolescents with Dravet syndrome
Epilepsy & Behavior·2022· 10 cited
Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression
Nature Communications·2020· 183 citedOpen Access
Biocompatible, Purified VEGF-A mRNA Improves Cardiac Function after Intracardiac Injection 1 Week Post-myocardial Infarction in Swine
Molecular Therapy — Methods & Clinical Development·2018· 167 citedOpen Access
Reassessing Phase II Heart Failure Clinical Trials
Circulation Heart Failure·2017· 15 citedOpen Access
Dual A1/A2B Receptor Blockade Improves Cardiac and Renal Outcomes in a Rat Model of Heart Failure with Preserved Ejection Fraction
Journal of Pharmacology and Experimental Therapeutics·2016· 19 citedOpen Access
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE
Journal of Neurology·2014· 23 cited
Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab‐associated progressive multifocal leukoencephalopathy
Annals of Neurology·2014· 427 citedOpen Access
MS disease activity in RESTORE
Neurology·2014· 188 citedOpen Access
Anti‐<scp>JC</scp> virus (<scp>JCV</scp>) antibody prevalence in the <scp>JCV</scp> Epidemiology in <scp>MS</scp> (<scp>JEMS</scp>) trial
European Journal of Neurology·2013· 98 cited
Longitudinal Stability of Anti-JC Virus Antibody Status in Multiple Sclerosis Patients: Results of STRATIFY-1 (S30.001)
Neurology·2013
JCV Epidemiology in MS (JEMS): prevalence of anti-JC virus antibodies in multiple sclerosis patients
2012· 1 cited
Effects of a 24-Week Natalizumab Treatment Interruption on Quality of Life, Fatigue, and Cognition: Results from the RESTORE Study (P06.171)
Neurology·2012· 1 cited
Pharmacokinetics and pharmacodynamics of tonapofylline in subjects with severe renal impairment and in elderly subjects
International Journal of Clinical Pharmacology and Therapeutics·2011· 2 cited
Natalizumab treatment interruption: RESTORE study baseline data
2011
Effects of BG9928, an Adenosine A<sub>1</sub>Receptor Antagonist, in Patients With Congestive Heart Failure
The Journal of Clinical Pharmacology·2010· 18 cited
Clinical Pharmacokinetics of Tonapofylline: Evaluation of Dose Proportionality, Oral Bioavailability, and Gender and Food Effects in Healthy Human Subjects
The Journal of Clinical Pharmacology·2010· 7 cited
Rationale and Design of the Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation (THE BALANCE) Study
Clinical and Translational Science·2010· 32 citedOpen Access
Pharmacokinetics (PK) of Adenosine A1 Receptor Antagonist BG9928 in Healthy Subjects, Elderly Subjects, and Subjects with Severe Renal Insufficiency (SRI)
Journal of Cardiac Failure·2009
page 1 of 2Next →

Frequent Co-authors

E. Whalley(10), Alan Gill(6), Kathleen Wortham(6), William T. Abraham(5), Shathabish S. Kariyanna(5), Robert P. Light(5), Tatiana Plavina(4), Meena Subramanyam(4), Sandra Richman(4), Stephen S. Gottlieb(4), Bruce Cree(4), Douglas Jeffery(4), Ludwig Kappos(4), Xavier Montalbán(4), Suzanne K. Swan(4), Rajiv Agarwal(4), Sophia Lee(3), Ignatius Thomas(3), Steven Goldman(3), Robert J. Fox(3)